Lajer M, Schjoedt K J, Jacobsen P, Tarnow L, Parving H-H
Steno Diabetes Center, Gentofte, Denmark.
Diabet Med. 2006 Jun;23(6):675-80. doi: 10.1111/j.1464-5491.2006.01871.x.
Aldosterone is one of the main effectors of the renin-angiotensin-aldosterone system regulating blood pressure. Previous studies have shown that the aldosterone synthase promoter polymorphism -344T/C influences aldosterone levels and is associated with hypertension, a risk factor for the initiation and progression of diabetic nephropathy. Therefore, we investigated whether the -344T/C polymorphism is associated with the development and progression of diabetic nephropathy in Type 1 diabetes mellitus.
The -344T/C polymorphism was determined using standard PCR techniques in 422 Type 1 diabetic patients with overt diabetic nephropathy [mean age 43 years (SD 11)], and in 479 patients with persistent normoalbuminuria and long-standing Type 1 diabetes [age 47 years (SD 12), duration of diabetes 27 years (SD 10)]. Furthermore, we genotyped 163 Type 1 diabetic patients with overt diabetic nephropathy treated with angiotensis-converting enzyme inhibitors (ACE-I). These patients were followed for a median of 6 years (range 3-14), with nine measurements (range 3-29) of glomerular filtration rate (GFR), and had a decline in GFR of 3.1 (-3.2; 23.7) ml/min per year.
There was no significant difference between cases and controls in either genotype distributions (cases TT 0.33, TC 0.48, CC 0.19; controls TT 0.32, TC 0.48, CC 0.20) or allele frequencies (cases T/C 0.57/0.43; controls T/C 0.56/0.44). Furthermore, a genotype-phenotype interaction analysis in the normoalbuminuric patients revealed no differences in sex distribution, age, duration of diabetes, blood pressure, HbA(1c,) or urinary albumin excretion rate across genotypes. In the observational follow-up study, the rate of decline in GFR did not differ between groups of patients with different -344T/C genotype (P = 0.41). However, the T-allele made a statistically significant contribution to both systolic and diastolic pressure during follow-up (P = 0.006 and 0.032, respectively).
The -344T/C polymorphism of the aldosterone synthase gene is not associated with initiation or progression of diabetic nephropathy in Caucasian Type 1 diabetic patients, but modulates blood pressure variation.
醛固酮是肾素 - 血管紧张素 - 醛固酮系统中调节血压的主要效应因子之一。既往研究表明,醛固酮合酶启动子多态性 -344T/C 影响醛固酮水平,并与高血压相关,而高血压是糖尿病肾病发生和进展的危险因素。因此,我们研究了 -344T/C 多态性是否与 1 型糖尿病患者糖尿病肾病的发生和进展相关。
采用标准 PCR 技术,对 422 例显性糖尿病肾病的 1 型糖尿病患者 [平均年龄 43 岁(标准差 11)] 以及 479 例持续性正常白蛋白尿且患 1 型糖尿病时间较长的患者 [年龄 47 岁(标准差 12),糖尿病病程 27 年(标准差 10)] 进行 -344T/C 多态性检测。此外,我们对 163 例接受血管紧张素转换酶抑制剂(ACE-I)治疗的显性糖尿病肾病 1 型糖尿病患者进行基因分型。这些患者的随访时间中位数为 6 年(范围 3 - 14 年),进行了 9 次(范围 3 - 29 次)肾小球滤过率(GFR)测量,GFR 每年下降 3.1(-3.2;23.7)ml/min。
病例组和对照组在基因型分布(病例组 TT 0.33,TC 0.48,CC 0.19;对照组 TT 0.32,TC 0.48,CC 0.20)或等位基因频率(病例组 T/C 0.57/0.43;对照组 T/C 0.56/0.44)方面均无显著差异。此外,对正常白蛋白尿患者进行的基因型 - 表型相互作用分析显示,不同基因型在性别分布、年龄、糖尿病病程、血压、糖化血红蛋白(HbA1c)或尿白蛋白排泄率方面无差异。在观察性随访研究中,不同 -344T/C 基因型患者组的 GFR 下降速率无差异(P = 0.41)。然而,在随访期间,T 等位基因对收缩压和舒张压均有统计学显著贡献(分别为 P = 0.006 和 0.032)。
醛固酮合酶基因的 -344T/C 多态性与白种人 1 型糖尿病患者糖尿病肾病的发生或进展无关,但可调节血压变化。